Mark H. Stoler, MD, FASCP

Drs Emily K. Hill, Sangini S. Sheth, and Mark H. Stoler share practice pearls for HPV and cervical cancer screening and express their hope for emerging testing options.

Experts in obstetric and gynecologic management provide insight on the role of HPV genotypes in cervical cancer risk.

Mark H. Stoler, MD, FASCP, provides insight on the role of dual testing in the management of HPV positive women.

Drs Sangini S. Sheth and Mark H. Stoler share their thoughts on the adoption of primary HPV screening and how they foresee changes to cervical cancer screening as more individuals get vaccinated.

Thomas C. Wright Jr., MD; Emily K Hill, MD; and Sangini S. Sheth, MD, MPH, FACOG, comment on the impact COVID-19 had on HPV and cervical cancer screening in their respective practices.

Drs Emily K. Hill, Sangini S. Sheth, and Mark H. Stoler, comment on the implementation considerations surrounding HPV and cervical cancer screening.

Emily K. Hill, MD, reviews the current US HPV and cervical cancer screening guidelines from the American Cancer Society, American College of Obstetricians and Gynecologists, and the American Society for Colposcopy and Cervical Pathology and discusses the differences within.

Experts in obstetric and gynecologic management examine conventional cervical cancer screening strategies and consider their specificity and sensitivity targets.

Drs Mark H. Stoler, Emily K. Hill, Sangini S. Sheth, and Thomas C. Wright comment on the general awareness around HPV and cervical cancer in patients as well as the importance of increasing routine cervical cancer screening approaching those conversations with patients.

Emily K. Hill, MD; Sangini S. Sheth, MD, MPH, FACOG, and Mark. H. Stoler, MD, FASCP, review the rationale of screening for HPV and vaccinating patients to prevent progression to cervical cancer.